J&J ends Palomar deal
This article was originally published in The Gray Sheet
Executive Summary
Palomar says it will move forward with commercialization of its home-use, light-based technology for treatment of cellulite, skin aging and acne after Johnson & Johnson backed out of an agreement to market the product, citing economic conditions. The Burlington, Mass.-based firm received 510(k) clearance for the device for treatment of periorbital wrinkles in June (1"The Gray Sheet" June 15, 2009). Citing a multi-billion dollar market opportunity, Palomar CEO Joseph Caruso said the firm plans to launch the device for multiple applications in the second half of 2010. Near-term marketing efforts will focus on "certain specialty channels," Caruso said